Related Experiment Video
Updated: Jan 21, 2026

Author Spotlight: Advancements and Challenges in Surgical Treatments for Postamputation Pain
Published on: March 8, 2024
Vitamin D Supplementation and T Cell Regulation in Preterm Infants: A Randomized Controlled Trial
Hany Aly1, Lamiaa Mohsen2, Indrani Bhattacharjee1
1Department of Neonatology, Cleveland Clinic Children's, Cleveland, OH.
Insights
Higher vitamin D3 doses (800 IU/day) significantly increased T regulatory cells (Treg) in preterm infants compared to lower doses (400 IU/day). This higher dose showed no short-term side effects, suggesting potential benefits for immune development in premature infants.
Area of Science:
- Immunology
- Neonatology
- Nutritional Science
Background:
- Premature infants often have vitamin D deficiency, impacting immune system development.
- T regulatory cells (Treg) are crucial for immune homeostasis and preventing autoimmunity.
- The optimal vitamin D dosage for Treg modulation in preterm infants remains unclear.
Purpose of the Study:
- To evaluate the effect of two different vitamin D3 doses on Treg cell expression in preterm infants.
- To assess short-term morbidity and mortality outcomes associated with vitamin D supplementation.
Main Methods:
- A double-blind randomized controlled trial involving 40 preterm infants (28-33 weeks gestational age).
- Infants received either 400 IU/day or 800 IU/day of vitamin D3 after achieving enteral feeds.
- Treg cell counts were measured via flow cytometry at baseline, 1 week, and 4 weeks; morbidity and mortality were also assessed.
Main Results:
- The 800 IU/day vitamin D3 group showed a significantly greater percentage increase in Treg cells after 1 week (60% vs 1.9%) and 4 weeks (73.7% vs 1.8%) compared to the 400 IU/day group.
- No significant differences were observed between groups in anthropometric measurements, oxygen/respiratory support duration, or mortality.
- The low-dose group experienced a longer hospital stay (24.9 days vs 22 days).
Conclusions:
- Oral vitamin D3 supplementation demonstrates a dose- and time-dependent effect on Treg cell percentages in preterm infants.
- The 800 IU/day dose of vitamin D3 appears safe in the short term for this population.
- Further research is warranted to investigate the long-term effects of vitamin D3 dosing on clinical outcomes like hospital stay duration.
Abstract:
The objective of this study was to evaluate the effect of 2 different doses of vitamin D on the expression of T regulatory cells (Treg) in premature infants. A double-blind randomized controlled trial was conducted on preterm infants born with gestational age between 28 and 33 weeks. Subjects were randomly assigned to receive 400 or 800 IU/day of vitamin D3 when they achieved 100 mL/kg of enteral feeds. Percentage increase in Treg cell counts were measured by flow cytometry at enrollment, and after 1 and 4 weeks of oral vitamin D supplementation at the allotted doses in both groups. Short-term morbidity and mortality outcomes were also assessed. A total of 40 infants were enrolled, 20 in each group. The change in Treg count (%) was significantly less in the low-dose vitamin D3 supplementation group after 1 week (1.9 ± 5.5 vs 60 ± 5.6, P = 0.0005) and after 4 weeks (1.8 ± 5.7 vs 73.7 ± 5.6, P = 0.0028). The 2 groups did not differ in anthropometric measurements, duration of oxygen and respiratory support, and mortality. Length of hospital stay was longer in the low-dose group (24.9 ± 5.14 vs 22 ± 3.49, P = 0.04). Oral vitamin D supplementation has a dose and time dependent effect on percentage of Treg in infants born prematurely. The 800 IU dose of vitamin D3 did not have apparent short-term side effects. Larger studies are needed to explore the effect of vitamin D3 dosing on length of hospital stay.
More Related Videos
Related Concept Videos
Vitamins
pH Regulation in Cells
Cytosolic pH
Under physiological conditions, the cytosolic pH is slightly more acidic than the extracellular pH. However, cells must prevent further acidification of their cytosol to...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Cooperative Binding of Transcription Regulators
Clinical Trials: Overview
Trial and Error and Algorithm

